ShareValue scores for LENZ: Valuation 59, Quality 37, Growth 66, Health 53.

LENZ Therapeutics Inc logo

LENZ
NASDAQ

LENZ Therapeutics Inc

$5.22(-0.95%)
Loading chart...
Sentiment

Verdicts

Rating

Trap Risk

Return

7% to 18%
Valuation
59
Fair Value
Price vs Value
Quality
37
Weak
Business Strength
Growth
66
Moderate
Revenue & Earnings
Health
53
Moderate
Financial Stability
Momentum
11
Bearish
Price Trend

Company Details

About

LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.

Score Analysis

AI Investment Thesis

Data as of:Aug 7, 2026
|
Last calculated:Aug 7, 2026